Capricor Therapeutics has entered into a partnership with Nippon Shinyaku for the exclusive commercialization and distribution in Japan of Capricor’s lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy, a rare neuromuscular disease with limited treatment options. This follows the exclusive Commercialization and Distribution Agreement entered into with Nippon Shinyaku in the United States in January 2022 Under the terms of the agreement, Capricor will receive an upfront payment of $12M and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89M and a meaningful, double-digit share of product revenue. This agreement is similar to the terms of the U.S. agreement with Nippon Shinyaku, in that Capricor will be responsible for clinical development and Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan, once approved. Capricor will sell commercial product to Nippon Shinyaku. In addition, Capricor will hold the Marketing Authorization in Japan, if the product is approved in that territory.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CAPR:
- Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
- Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
- Capricor announces 18-month results from ongoing HOPE-2 OLE study of CAP-1002
- Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
- Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform